Press releaseBusiness Wire
Viridian Therapeutics
VRDN · NASDAQ
$22.43+$0.05 (+0.22%)TodayMarket closed ·
Prev close $22.38
Latest news
- NewsVandana Singh
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
- NewsTim Melvin
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
- Press releaseBusiness Wire
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
- NewsVandana Singh
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
- NewsRishabh Mishra
Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)
- NewsAvi Kapoor
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
- Press releaseBusiness Wire
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
- Press releaseBusiness Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
- Press releaseBusiness Wire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
- Press releaseBusiness Wire
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
- Press releaseBusiness Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
- NewsVandana Singh
Why Is Viridian Therapeutics Stock Sinking Monday?
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Crude Oil Rises Over 2%; US Dallas Fed Manufacturing Index Declines In March
- NewsAvi Kapoor
Dow Gains 200 Points; Bullfrog AI Shares Jump
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseBusiness Wire
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
- News
Earnings Breakdown: Viridian Therapeutics Q4
- Press releaseBusiness Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releaseBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Viridian Therapeutics Prepares for Transformational 2026
- NewsNamrata Sen
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
- Press releaseBusiness Wire
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
- NewsVandana Singh
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
- Press releaseBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
- Press releaseBusiness Wire
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
- Press releaseBusiness Wire
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
- News
Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts
- NewsAvi Kapoor
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.